Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30)

• Published in: JNCI cancer spectrum 2024-11, Vol.8 (6)
• Main Authors: Chen, Ronald C, Basak, Ramsankar, Dusetzina, Stacie, Usinger, Deborah S, Mohammed, Zahed, Falchook, Aaron D, Schumacher, Jessica R, Francescatti, Amanda B, Cuddy, Amanda, Chang, George J, Kozower, Benjamin D, Greenberg, Caprice C, Barber, Anne K, Katz, Aaron J
• Format: Article
• Language: English
• Subjects: Aged; Biopsy; Cancer Survivors - statistics & numerical data; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen - blood; Prostatectomy - mortality; Prostatic Neoplasms - blood; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; Prostatic Neoplasms - surgery; Prostatic Neoplasms - therapy; Salvage Therapy - statistics & numerical data
• ISSN: 2515-5091; 2515-5091
• DOI: 10.1093/jncics/pkae099

Background Posttreatment surveillance affects millions of cancer survivors, but empiric data to guide clinical practice are lacking. This study assessed whether the intensity of surveillance testing after radical prostatectomy or radiation therapy for localized prostate cancer is associated with overall survival. Methods Men diagnosed with localized prostate cancer between 2005 and 2010 who underwent radical prostatectomy or radiation therapy at a Commission on Cancer–accredited facility were randomly sampled. Primary data collected from 10 147 patients sampled across 1007 facilities were linked with existing data from the National Cancer Database. Analysis examined whether intensity of surveillance measured as the number of prostate-specific antigen (PSA) tests in the first year after primary treatment (categorized as 0-1 [low intensity], 2 [medium], or ≥3 [high intensity] PSA tests) was associated with overall survival. Secondary outcomes included recurrence-free survival (RFS) and subsequent use of imaging tests, biopsy procedures, and salvage treatment. Results Median follow-up exceeded 8 years from prostate cancer diagnosis. Overall survival was not statistically significantly different across surveillance intensity groups among radiation therapy (P = .59) or radical prostatectomy (P = .29) patients. RFS was not statistically significantly different across surveillance intensity groups for radiation therapy (P = .13) patients but was for radical prostatectomy (P = .01) patients with high intensity associated with the worst RFS. In both treatments, higher surveillance intensity was associated with more procedures and salvage treatments. Conclusions In patients with localized prostate cancer, more frequent PSA surveillance testing after radical prostatectomy or radiation therapy was associated with increased procedures and salvage treatments but not overall survival.